论文部分内容阅读
目的:评价PDCA循环管理法对质子泵抑制剂在临床使用中的作用。方法:采用用根本原因分析法找到主要原因,通过PDCA循环管理对质子泵抑制剂使用进行干预,从2014年1月起,每6月为一阶段,进行两阶段的循环管理;利用医院信息系统(HIS)抽取2013年6月—2014年12月间使用的质子泵抑制剂的病历1 697份,将其分成3组,即干预前组(2013年6—12月)使用质子泵抑制剂的病历545份,干预组-1(2014年1—6月)使用质子泵抑制剂的病历608份,干预组-2(2014年6—12月)使用质子泵抑制剂的病历544份;比较干预前后质子泵抑制剂的规范使用率及预防规范使用率。结果:医院质子泵抑制剂规范使用率从干预前13.58%上升至干预后79.78%,预防规范使用率从干预前1.28%上升至干预后43.38%。结论:通过PDCA循环管理的运用,临床质子泵抑制剂的使用已逐步规范化和合理化。
PURPOSE: To evaluate the role of PDCA cycle management in the clinical use of proton pump inhibitors. Methods: The root cause analysis was used to find out the main reasons. PDCA cycle management was used to intervene the use of proton pump inhibitors. From January 2014 onwards, one phase was conducted every June for two phases of cycle management. Using hospital information system (HIS) collected 1 697 medical records of proton pump inhibitors used between June 2013 and December 2014, and divided them into 3 groups, namely, the former group (June-December 2013) using proton pump inhibitors 545 cases of medical record, 608 cases of using proton pump inhibitor in intervention group-1 (January-June 2014), and 544 cases of using proton pump inhibitor in intervention group-2 (June-December 2014) The standard usage of proton pump inhibitor before and after, and the usage of prevention norms. Results: The standard utilization rate of proton pump inhibitor in hospital increased from 13.58% before intervention to 79.78% after intervention, and the preventive usage rate increased from 1.28% before intervention to 43.38% after intervention. CONCLUSIONS: The use of PDCA inhibitors has been standardized and rationalized through the use of PDCA cycle management.